1515
Annons
Elicera Therapeutics: BioStock: Elicera Therapeutic's iTANK-platform reaches proof-of-concept

Elicera Therapeutics presented preclinical proof-of-concept data for its patented iTANK platform this week. The data helps make the case that iTANK, used for the optimisation of immunotherapies, enables CAR T-cell therapies to overcome two of the major challenges in treating solid tumours. Until now, conventional CAR T-cell therapies have been unable to treat solid tumours.

Read the article at biostock.se:

https://www.biostock.se/en/2021/10/elicera-therapeutics-itank-platform-reaches-proof-of-concept/

This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se

Source: Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera